HMGB1 and colorectal cancer: This study focused on the expression and changes of HMGB1 in the serum of colorectal cancer patients with liver metastasis before and after TACE, and we explored the possibility of predicting liver injury, adverse reaction, and PFS after TACE by monitoring the changes of HMGB1.